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Abstract
Background: In comparison to the conventional whole-prostate dose escalation, an integrated boost to the
macroscopic malignant lesion might potentially improve tumor control rates without increasing toxicity. Quality of
life after radiotherapy (RT) with vs. without 18F-choline PET-CT detected simultaneous integrated boost (SIB) was
prospectively evaluated in this study.
Methods: Whole body image acquisition in supine patient position followed 1 h after injection of 178-355MBq
18F-choline. SIB was defined by a tumor-to-background uptake value ratio > 2 (GTVPET). A dose of 76Gy was
prescribed to the prostate (PTVprostate) in 2Gy fractions, with or without SIB up to 80Gy. Patients treated with
(n = 46) vs. without (n = 21) SIB were surveyed prospectively before (A), at the last day of RT (B) and a median
time of two (C) and 19 month (D) after RT to compare QoL changes applying a validated questionnaire (EPIC -
expanded prostate cancer index composite).
Results: With a median cut-off standard uptake value (SUV) of 3, a median GTVPET of 4.0 cm
3 and PTVboost (GTVPET with
margins) of 17.3 cm3 was defined. No significant differences were found for patients treated with vs. without SIB
regarding urinary and bowel QoL changes at times B, C and D (mean differences ≤3 points for all comparisons).
Significantly decreasing acute urinary and bowel score changes (mean changes > 5 points in comparison to baseline
level at time A) were found for patients with and without SIB. However, long-term urinary and bowel QoL (time D) did
not differ relative to baseline levels - with mean urinary and bowel function score changes < 3 points in both groups
(median changes = 0 points). Only sexual function scores decreased significantly (> 5 points) at time D.
Conclusions: Treatment planning with 18F-choline PET-CT allows a dose escalation to a macroscopic intraprostatic
lesion without significantly increasing toxicity.
Keywords: prostate cancer, intensity-modulated radiotherapy, simultaneous integrated boost, choline PET, quality
of life
Background
Increasing doses for prostate cancer have been shown to
be associated with improved biochemical control rates
in several prospective randomized studies [1]. However,
rectal toxicity has also increased significantly. Rectal
toxicity is known to be the dose-limiting toxicity in
prostate cancer radiotherapy [2,3]. Focusing the dose
escalation on the actual tumour has the potential to
increase tumour control without increasing toxicity.
Local prostate cancer recurrence after primary radio-
therapy (RT) usually originates in the location of the
primary tumor. Cellini et al. found the origin of all local
recurrences within the initial tumor volume, supporting
the rationale of a selective dose escalation only to the
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intraprostatic lesion [4]. In view of an often multifocal
microscopic spread of prostate cancer [5] - not possible
to delineate with the presently available imaging modal-
ities - the whole prostate has still to be covered by an
effective dose.
Treatment was based on 18F-choline PET-CT (positron
emission tomography and computed tomography acquired
in same patient position) for patients in focus of this
study. A simultaneous integrated boost (SIB) was delivered
to the GTVPET (gross target volume, as defined in PET).
Quality of life (QoL) changes were evaluated prospectively
and compared to a patient group treated with the same
concept in the same time interval - but without a SIB - to
demonstrate an acceptable treatment tolerance and a
rationale to continue this innovative strategy.
In contrast to grading scales, for example the com-
monly applied RTOG/EORTC (Radiation Therapy
Oncology Group/European Organisation of Research and
Treatment of Cancer) scale, QoL questionnaires have the
advantage of revealing all grades of toxicity from the
patient’s perspective. Baseline problems can be taken into
account accurately.
Methods
Treatment planning
This prospective study was based on consecutive patients
who were treated due to localized T1-3N0M0 prostatic
carcinoma in the years 2008-2009. PET-CT (Philips
Gemini TF 16) with 18F-choline was performed in 46
patients for treatment planning. Image acquisition in
supine patient position followed 1 h after injection of 178-
355MBq 18F-choline. Images were reconstructed using the
iterative LOR (line of response) algorithm (pixel size: 4
mm3). CT images (from PET-CT) with a slice thickness of
3 mm were used for treatment planning.
The CTV (prostate volume ± base of seminal vesicles),
bladder and rectum (region from anal canal to the recto-
sigmoid flexure) were delineated by identifying the exter-
nal contours (Philips Pinnacle3 Version 8.0 m). GTVPET
(intraprostatic lesion) was defined by a tumour-to-back-
ground choline uptake ratio > 2, based on the results of
studies correlating choline PET results with histopatholo-
gic examinations [6,7]. We have identified an area of
about 1 cm2 within the prostate with the lowest activity
and defined the threshold for GTVPET after multiplying
the SUVmax (maximum standard uptake value) in this area
by 2 [8].
For the planning target volume (PTV), 8 mm lateral
and anterior, 5 mm superior and inferior and 4 mm pos-
terior margin was added. A uniform margin of 4 mm was
added to the GTVPET to account for intrafraction target
motion, with the exception of the posterior direction (3
mm). Intrafraction prostate displacements have been
evaluated in our department recently using ultrasound
based image-guided radiotherapy (IGRT) - the required
margins were calculated to be ≤4 mm in all directions,
with 85% of displacements within a margin of 3 mm [9].
Ultrasound based IGRT was applied before each fraction
for patient positioning for all patients using the BAT®
SXi system (B-mode acquisition and targeting).
An inverse planning with a five field step-and-shoot
intensity-modulated radiotherapy (IMRT) technique and
15MeV photons was used. The direct machine para-
meter optimization (DMPO) algorithm was applied for
inverse planning with a 2 cm2 minimum segment area,
5 minimum segment monitor units and a maximum
number of 70 segments. The dose to the PTV was pre-
scribed to a reference point (outside the volume of
GTVPET). Treatment planning objectives are sum-
marised in Table 1. Examples are shown in Figure 1.
Table 1 Treatment planning objectives
region of interest type objective
PTVboost uniform dose =
prescription dose to GTVPET
80Gy
PTVboost dose homogeneity +/-5%
CTVprostate minimum dose 76Gy
PTVprostate minimum dose 72Gy
[95% of prescription dose]
PTVprostate - PTVboost uniform dose =
prescription dose to PTV
76Gy
Rectum maximum dose 76Gy
(constraint)
Rectum maximum dose to 20% volume 70Gy
Rectum maximum dose to 50% volume 50Gy
Bladder maximum dose to 30% volume 70Gy
Bladder maximum dose to 50% volume 55Gy
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Quality of life and treatment plans for patients who
were treated with SIB were compared with patients trea-
ted without SIB in the same period (n = 21) - boost
volume has either have not been defined or 18F-choline
PET-CT has not been performed due to logistic reasons.
Tumour based criteria had no relevance for the selec-
tion to treat with or without SIB. With the exception of
the SIB, the same treatment planning and treatment
delivery technique was used for patients without SIB
(daily IGRT and five field IMRT).
We have focused on the EUD (equivalent uniform
dose) for the PTV, rectum and bladder and the NTCP
(normal tissue complication probability) for the rectum
and bladder.
EUD =
(
1
N
∑
i
Dai
)1
a
N = voxel number; Di = dose in the i’th voxel; a =
tumour or normal tissue-specific parameter that
describes the dose-volume effect; with a = -10 for pros-
tate cancer and a = 6 for bladder and rectum in this
study [8].
NTCP for grade 3 or worse rectum and bladder toxi-
city was computed applying the Lyman-Kutcher-Burman
model with Emami parameters (rectum: n = 0.12, m =
0.15, median toxicity dose = 80Gy; bladder: n = 0.5, m =
0.11; median toxicity dose = 80Gy) [10,11].
Figure 1 Simultaneous integrated boost concept for two patients with a PET-CT slice (images on the left, PET signal demonstrates the
malignant lesion above a fixed standard uptake value threshold) and the corresponding contours and isodose lines in a treatment
plan (images on the right).
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Quality of life evaluation
Patients were surveyed prospectively before (time A), at
the last day (B), and a median time of two months (range
6 weeks-6 months) after (C) and 19 months (range 14-24
months) after (D) radiotherapy using a validated question-
naire, the Expanded Prostate Cancer Index Composite
(EPIC) [12,13]. The questionnaire comprises 50 items con-
cerning the urinary, bowel, sexual and hormonal domains
for function and bothersomeness. The multi-item scale
scores were transformed lineary to a 0-100 scale, with
higher scores representing better QoL. According to data
in the literature, mean QoL changes of below 5 points can
be defined as clinically not significant, 5-10 as “little”
changes, 10-20 as “moderate” changes and > 20 as “very
much” changes [14]. Other authors use the “0.5 standard
deviation of baseline value” to determine clinically relevant
changes [14] - this is also reported in this study. A baseline
questionnaire was required for inclusion in this study
resulting in a total number of 46/21 (time A), 38/16 (time
B), 44/21 (time C) and 44/20 (time D) questionnaires after
treatment with/without SIB.
The questionnaire was handed over to the patients per-
sonally by one of the physicians at time A, B and C.
Number of questionnaires was the lowest at the end of
radiotherapy (time B) because this point in time was lim-
ited to a single day (last radiotherapy fraction) and there
was no second opportunity to fill out a missed question-
naire. Patients presented in the department six to ten
weeks after the end of treatment. Missed questionnaires in
the acute phase (time C) and questionnaires one to two
years after radiotherapy (time D) were sent to the patients
with a return envelope. If a questionnaire was not returned
within 4 weeks, patients were contacted by telephone and
were urged to complete it. The median time after treat-
ment and the respective ranges for the questionnaires C
and D were the same for patients after treatment with and
without SIB.
Statistical analysis
Statistical analysis was performed using the IBM SPSS 19.0
software. The Wilcoxon’s matched-pairs test was applied
to determine longitudinal changes in specific subgroups of
patients. To explore statistical volume or dose differences
in treatment plans and QoL score differences between
different subgroups at a specific time, the Mann-Whitney-
U-test was used. Contingency table analysis with the chi-
square test was performed to compare treatment groups
with respect to categorical variables. All p-values reported
are two-sided, p < 0.05 is considered significant.
Results
Demographic and treatment plan-related data are pre-
sented in Table 2, showing well comparable (statistically
not significantly different) distribution of prognostic
factors and organ volumes for treatment planning. Med-
ian EUD values for patients treated with SIB were 2%
higher in comparison to patients without SIB, with
slightly higher NTCP for rectal toxicity. However, only
the EUD for PTVprostate was significantly higher for
patients treated with SIB (p > 0.05 for all other
comparisons).
With a median cut-off standard uptake value (SUV) of 3,
a median GTVPET of 4.0 cm
3 and PTVboost (GTVPET with
margins) of 17.3 cm3 was defined. Malignant lesions were
defined as single lesions in 31%, as two bilateral lesions in
26%, as central lesions extending into both lobes in 30%
and as multiple (at least three) lesions in 13%.
Baseline QoL scores have not been found to be signifi-
cantly different (Table 3) for patients treated with or
without SIB. No significant differences were found
regarding urinary, bowel and sexual QoL changes at
times B, C and D (mean differences ≤3 points for all
comparisons in urinary and bowel domains). Significantly
decreasing acute urinary and bowel scores changes (clini-
cally relevant: mean changes > 5 points in comparison to
baseline level at time A; > 0.5 standard deviation of base-
line value) were found for patients with and without SIB.
However, long-term urinary and bowel QoL (time D) did
not differ relative to baseline levels - with mean urinary
and bowel function score changes < 3 points in both
groups (median changes = 0 points).
Only sexual scores decreased significantly (> 5 points; all
mean changes < 0.5 standard deviation of baseline value)
at time D. As sexual scores demonstrate the largest varia-
bility (Table 3), a possible decrease strongly depends on
the baseline scores. Sexual function scores of patients with
a baseline sexual function score < 25 did not change > 5
points at time D in comparison to baseline in both sub-
groups. However, sexual function scores of patients with a
baseline sexual function scores of 25-50 and > 50
decreased 12 points in both subgroups and 11/15 points
in the subgroup treated with/without SIB, respectively.
Considering only patients with higher baseline scores
(> 25 points), changes more than a year after the end of
radiotherapy also exceeded the 0.5 of standard deviation
threshold (p < 0.01 and p = 0.02 with and without SIB). At
time D, 75% and 60% of patients in the prostate with SIB
and prostate only groups who reported erections sufficient
for sexual intercourse before treatment retained this
ability.
The rates of reporting big or moderate bother with spe-
cific symptoms are shown in Table 4. In accordance with
the corresponding scores, the greatest changes were
reported in the acute phase at the end of treatment for
irritative symptoms - or urinary and bowel function over-
all. Significant differences between the subgroups with or
without SIB have not been found. Remarkably, not a single
patient reported big or moderate bother with bloody stools
Pinkawa et al. Radiation Oncology 2012, 7:14
http://www.ro-journal.com/content/7/1/14
Page 4 of 9
at times C or D. Mean bleeding function scores were 98
points at all response intervals (times A, B, C and D) in
the subgroup with SIB.
GTVPET volumes and distances to the bladder and
rectum wall were evaluated in the subgroup of patients
who were treated with SIB (Table 5; < or ≥median,
respectively). A tendency for larger QoL changes was
found for patients with larger GTVPET volumes and clo-
ser distances to the bladder and rectum wall. In con-
trast to a faster return to baseline levels at time C of
patients with GTVPET < 4 cm
3, a distance to the blad-
der ≥1 cm and a distance to the rectum wall ≥3 mm,
scores of patients with GTVPET > 4 cm
3 (bowel bother)
a distance to the bladder < 1 cm (urinary bother) and a
distance to the rectum wall < 3 mm (bowel bother)
were still significantly higher at time C in comparison
to baseline levels. The difference exceeded 5 points and
the 0.5 standard deviation of baseline level threshold
with the exception urinary bother scores in case of a
GTVPET > 4 cm
3. No statistically significant differences
relative to baseline levels were found in any subgroup at
time D.
Discussion
The whole prostate is the standard target volume for
external beam radiotherapy and brachytherapy for loca-
lised prostate cancer, as prostate cancer is known to be
a multifocal disease and diagnosis of microscopic cancer
is not possible with presently available imaging modal-
ities [5]. However, advances in imaging and radiotherapy
techniques offer innovative treatment possibilities [15].
Treatment planning with 18F-choline PET-CT allows a
dose escalation to a macroscopic intraprostatic lesion
without increasing toxicity.
Magnetic resonance imaging (MRI), magnetic reso-
nance spectroscopy (MRS) and choline PET/CT are sui-
table methods to localize intraprostatic lesions with an
adequate sensitivity and specificity [6,7,16,17]. Choline
acts as a precursor for the biosynthesis of phospholipids,
e.g. phosphatidylcholine, the major component of the
plasma membrane. The uptake of choline reflects both
proliferation and signaling in transformed cells [18]. Ele-
vated choline to citrate ratios are used to discriminate
prostate cancer in MRS imaging [16]. Disadvantages of
MRS in comparison to PET imaging are larger voxel
Table 2 Demographic and treatment plan-related data
prostate with SIB (n = 46) prostate only (n = 21)
patient age/years
median (range)
72 (59-83) 71 (61-81)
PTVprostate /cc
median (range)
142 (35-310) 163 (70-537)
PTVboost /cc
median (range)
17 (4-46) -
% PSA ≤10 ng/mL 74% 76%
% Gleason score ≤6 65% 71%
% T-stage ≤2a 78% 86%
% NHT 17% 19%
bladder volume/cc
median (range)
237 (69-645) 225 (98-493)
rectum volume/cc
median (range)
88 (36-235) 81 (48-252)
EUD PTVprostate*/Gy
median (range)
76.7 (73.8-78.3) 76.0 (74.3-77.1)
EUD PTVboost /Gy
median (range)
79.5 (76.6-80.5) -
EUD bladder/Gy
median (range)
55.6 (41.7-63.2) 54.6 (45.0-62.3)
EUD rectum/Gy
median (range)
55.9 (47.1-62.4) 54.6 (40.1-60.6)
NTCP bladder/%
median (range)
0 (0-0.6) 0 (0-0.4)
NTCP rectum/%
median (range)
6.9 (2.2-14.7) 5.5 (1.5-11.2)
Abbreviations: PTV = planning treatment volume; PSA = prostate-specific antigen; NHT = neoadjuvant hormonal therapy; EUD = equivalent uniform dose; NTCP =
normal tissue complication probability
*p < 0.01
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sizes (usually at least 1 cm3 vs. 4 mm3) and a more
strenuous and subjective analysis of the data.
Image-guided radiotherapy (IGRT) and IMRT are pre-
requisites for applying the simultaneous integrated boost
concept. IGRT techniques eliminate inaccuracies due to
interfractional prostate displacement and help to mini-
mize safety margins considerably. IMRT brings the
opportunity to deliver heterogeneous dose prescriptions
Table 4 Rates of reporting big or moderate bother with specific symptoms
time A time B time C time D
dripping or leaking urine prostate with SIB 7% 11% 5% 2%
prostate only 10% 6% 14% 15%
need to urinate frequently prostate with SIB 22% 46% 26% 16%
prostate only 19% 50% 38% 25%
urinary function overall prostate with SIB 9% 38% 18% 9%
prostate only 24% 38% 33% 15%
urgency to have a bowel movement prostate with SIB 7% 19% 12% 10%
prostate only 14% 18% 14% 10%
losing control of stools prostate with SIB 0% 3% 5% 7%
prostate only 0% 6% 10% 0%
bloody stools prostate with SIB 0% 0% 0% 0%
prostate only 0% 6% 0% 0%
bowel habits overall prostate with SIB 4% 13% 14% 12%
prostate only 10% 25% 14% 10%
sexual function overall prostate with SIB 49% 46% 52% 68%
prostate only 50% 31% 41% 53%
Table 3 Mean function an bother scores before treatment and differences after treatment relative to baseline scores
(quartiles in brackets; negative differences indicate a quality of life improvement)
time A 0.5 SD time A-time B time A-time C time A-time D significant differences
A vs. B A vs. C A vs. D
urinary function score prostate with SIB 94
(94;100;100)
6 12
(0;9;20)
5
(0;0;7)
1
(0;0;7)
+ + -
prostate only 89
(87;100;100)
9 9
(0;3;18)
3
(-3;0;8)
2
(0;0;8)
+ - -
urinary bother score prostate with SIB 82
(75;86;96)
8 17
(0;18;32)
2
(-10;0;11)
0
(-10;0;6)
+ - -
prostate only 79
(63;86;98)
10 20
(2;14;37)
6
(-4;4;20)
0
(-7;0;13)
+ - -
bowel function score prostate with SIB 92
(89;96;100)
5 10
(0;11;19)
3
(-3;0;7)
1
(-4;0;4)
+ - -
prostate only 90
(89;96;100)
6 14
(1;14;24)
3
(-4;4;9)
-1
(-6;0;7)
+ - -
bowel bother score prostate with SIB 92
(89;100;100)
6 12
(0;14;21)
4
(0;0;10)
2
(0;0;4)
+ - -
prostate only 89
(79;100;100)
9 13
(1;9;24)
4
(-5;0;11)
-3
(-11;0;4)
+ - -
sexual function score prostate with SIB 35
(15;37;51)
12 7
(0;3;15)
7
(0;7;17)
5
(-3;5;18)
+ + -
prostate only 34
(11;30;54)
12 6
(0;9;14)
4
(-3;5;12)
11
(0;7;23)
- - +
sexual bother score prostate with SIB 51
(25;31;94)
18 7
(-2;3;20)
6
(0;6;19)
14
(0;0;28)
- - +
prostate only 57
(20;44;100)
19 4
(0;0;19)
-6
(-11;0;17)
8
(0;9;27)
- - -
Abbreviations: SD = standard deviation of baseline value
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Table 5 Mean bother scores before treatment and differences after treatment relative to baseline scores (quartiles in brackets; negative differences indicate
a quality of life improvement; bold numbers indicate significant difference between treatment groups)
time A 0.5 SD time A-time B time A-time C time A-time D significant differences
A vs. B A vs. C A vs. D
urinary bother score GTVPET < 4 cc 81
(75;84;92)
7 17
(-5;23;32)
0
(-11;-4;11)
1
(-11;-4;7)
+ - -
GTVPET ≥4 cc 83
(75;86;98)
8 15
(0;7;34)
5
(-9;0;14)
-2
(-9;0;4)
+ - -
urinary bother score distance GTVPET to bladder ≥1 cm 81
(75;86;90)
6 13
(2;14;37)
0
(-4;4;20)
-3
(-11;0;0)
+ - -
distance GTVPET to bladder < 1 cm 81
(75;82;96)
9 21
(0;21;37)
8
(-4;0;21)
4
(-7;0;11)
+ + -
bowel bother score GTVPET < 4 cc 89
(86;94;100)
8 10
(-4;14;27)
-1
(-7;0;4)
-1
(-7;0;4)
+ - -
GTVPET ≥4 cc 95
(89;100;100)
5 15
(1;12;21)
9
(0;2;14)
3
(0;0;4)
+ + -
bowel bother score distance GTVPET to rectum ≥3 mm 91
(89;96;100)
7 11
(0;12;19)
2
(-6;0;4)
-1
(0;0;4)
+ - -
distance GTVPET to rectum < 3 mm 91
(88;98;100)
7 14
(-6;14;27)
7
(0;4;11)
2
(0;0;5)
+ + -
Abbreviations: SD = standard deviation of baseline value
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within the target. The simultaneous integrated boost
concept has been rapidly adopted for the IMRT of head
and neck cancer patients [19]. Dose escalation in the
area of the primary macroscopic tumour is also applied
in several other regions, probably most frequently for
breast cancer - the clinical benefit on local control has
been demonstrated [20].
In a recently published study, an intraprostatic lesion
could be identified in 65 of 66 consecutive patients after
performing 18F-choline PET-CT [21]. GTVPET and SUV
levels were found to depend on prognostic risk factors,
particularly a Gleason score > 7. Increasing PET-defined
tumor volumes and increasing SUV levels correlated well
with increasing prognostic risk. Though antiandrogen
hormonal therapy is known to decrease choline uptake in
prostate cancer [19], the identification of a lesion is still
possible after NHT. SUV levels in intraprostatic lesions
were comparable to patients without NHT. NHT or a
prior radiation dose to the prostate reduces cell metabo-
lism and absolute SUV both in the tumour and the
benign prostate tissue [22]. A relative SUV threshold
seems to be a more reasonable definition for these
patients. The ratio between tumour and normal tissue is
the key to identifying aggressive disease [23].
Treatment planning studies evaluating the impact of
the simultaneous integrated boost have been already
published, demonstrating the potential of a considerable
dose escalation to the macroscopically defined tumor
without significantly increasing the dose to the organs at
risk or NTCP [8,24]. These results are supported by the
treatment plan-related data of the patients in this study.
EUD and NTCP values for the rectum and bladder have
not been found to differ significantly between patients
treated with or without SIB.
Quality of life evaluations after radiotherapy for pros-
tate cancer with a SIB have not been published before.
The results of this clinical study well support the results
of prior treatment planning studies [8,24]. The addi-
tional SIB did not increase QoL changes in the acute
phase or more than one year after radiotherapy. Gener-
ally, the treatment was very well tolerated. Even with
larger SIB volumes and close distances to the bladder
and/or rectum walls, mean long-term urinary and blad-
der QoL scores did not decrease more than 5 points (or
0.5 standard deviation) in comparison to the baseline
level. Treatment tolerance did not decrease in compari-
son to our patients who were treated up to total doses
of 70.2-72Gy using three-dimensional conformal plan-
ning without IGRT [2,3] (data presented in prior publi-
cations). In particular, rectal bleeding - usually in focus
of rectal toxicity after radiotherapy for prostate cancer
[2,3]- has not been found to be considerably relevant for
the patients. A clinically relevant QoL change was only
found in the sexual domain for patients with higher
baseline sexual function scores, without a significant dif-
ference with vs. without SIB.
Acute toxicity results up to three months after RT
with an MRI/MRS detected SIB have been published by
Fonteyne et al. [16]. An intraprostatic lesion was identi-
fied in only 118 of 230 patients - a considerably lower
percentage in comparison to treatment planning after
18F-choline PET-CT. The severity and incidence of
acute toxicity did not increase for patients treated with
SIB. However, the authors did not consider any margin
around the intraprostatic lesion.
Conclusions
According to the results of this prospective non-rando-
mized study, treatment planning with 18F-choline PET-
CT allows a dose escalation to a macroscopic intrapro-
static lesion without increasing toxicity. Previously
found significantly decreasing long-term bowel scores
(> 5 points) after conformal RT to doses of 70.2-72Gy
could be avoided after IMRT without and with SIB in
spite of increasingly higher total doses to the prostate
and specifically the intraprostatic malignant lesion.
The results are encouraging to continue evaluating
this concept in the future. Further results with longer
follow-up and larger patient groups are needed.
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